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The most frequent BCR-ABL1 fusion transcripts in chronic myeloid leukemia (CML) are the e13a2
(b2a2) and the e14a2 (b3a2) ones. In the imatinib era few studies addressing the prognostic signifi-
cance of the BCR-ABL1 transcript type in early chronic phase CML have been published. Overall,
these studies suggest that in e14a2 patients the response to imatinib is faster and deeper. To eval-
uate if the BCR-ABL1 transcript type (e13a2 compared to e14a2) affect the response to imatinib
and the clinical outcome in newly diagnosed adult CML patients, 559 patients enrolled in 3 pro-
spective studies (NCT00514488, NCT00510926, observational study CML/023) were analyzed. A
qualitative PCR was performed at baseline: 52% patients had a e14a2 transcript, 37% a e13a2
transcript, 11% co-expressed both transcripts and 1% had other rare transcripts. The median
follow-up was 76 months (95% of the patients had at least a 5-year observation). The complete
cytogenetic response rates were comparable in e14a2 and e13a2 patients. The median time to
MR3.0 (6 and 12 months) and MR4.0 (41 and 61 months) was significantly shorter for e14a2
patients compared to e13a2 patients, with a higher cumulative probability of MR3.0 (88% and
83%, P< .001) and MR4.0 (67% and 52%, P5 .001). The 7-year overall survival (90% and 83%,
P5 .017), progression-free survival (89% and 81%, P5 .005) and failure-free survival (71% and
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54%, P< .001) were significantly better in patients with e14a2 transcript. In conclusion, patients
with e13a2 transcript had a slower molecular response with inferior response rates to imatinib and
a poorer long-term outcome.
1 | INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloproliferative disorder char-
acterized by the presence of the BCR-ABL1 fusion gene. The BCR-
ABL1 gene encodes a constitutively active tyrosine kinase, which leads
to the activation of multiple signaling pathways involved in cell-cycle,
adhesion and apoptosis.1,2 The location of the breakpoints in the ABL1
and BCR genes is variable: the breakpoint in the ABL1 gene can occur
anywhere within a large area of more than 300 kb, while in the great
majority of CML patients the breakpoints of BCR gene cluster within
the Major Breakpoint Cluster Region (M-BCR). The M-BCR (5.8 kb)
span exons e12-e16, historically named b1-b5, but the transcribed
mRNA has either a e13a2 (b2a2) or a e14a2 (b3a2) junction. In 5-10%
of patients, both e13a2 and e14a2 transcripts may be detected by a
qualitative RT-QPCR. The fusion protein encoded by BCR-ABL1 varies
in size, depending on the breakpoints: both e13a2 and e14a2 mRNAs
encode a p210.1-3 In the era of conventional chemotherapy and inter-
feron, several studies have investigated whether the transcript type
may influence the outcome of CML patients: overall, these studies
failed to detect a significant and robust influence of transcript type on
response and clinical outcome.4–7 Imatinib mesylate (IM, Gleevec –
Novartis Pharma) is a 2-phenylaminopyrimidine derivative active in
Philadelphia-chromosome (Ph) positive CML through a selective inhibi-
tion of the BCR-ABL1 protein. In the last decade IM has become the
standard therapy of CML patients in early chronic phase (ECP).8–10 In
the IM era some studies addressing the prognostic significance of BCR-
ABL1 transcript type have been published, suggesting that in e14a2
patients the response to imatinib is faster and deeper.11–14 However,
the evidence is weak and mostly limited to response, particularly to
molecular response. A recent analysis, conducted within the European
Treatment and Outcome Study for CML (EUTOS) CML registry, did not
detect survival differences (overall survival and CML-related death)
according to the transcript type, but the response and other outcome
measures have not been investigated.15 Small differences are difficult
to detect, requiring large number of patients and prospective studies.
For this purpose, we have analyzed a large cohort of 559 patients who
were enrolled in prospective GIMEMA studies of treatment with IM in
first-line.
2 | METHODS
Five hundred and fifty-nine patients were consecutively enrolled in 3
concurrent multicentric prospective studies of the Italian Group for
Hematological Malignancies of Adults (GIMEMA) CML Working Party
(WP): CML/021 (Clin Trials Gov. NCT00514488), phase 2, exploring
IM 800 mg in intermediate Sokal risk CML patients16; CML/022 (Clin
Trials Gov. NCT00510926), phase 3, comparing IM 400 mg vs 800 mg
in high Sokal risk CML patients17; CML/023, observational, first-line
treatment with IM 400 mg.18 All patients, at least 18 years old, had a
Ph1 and/or BCR-ABL11 CML in ECP ( 6 months from diagnosis to
IM start; hydroxyurea only allowed). All patients provided written
informed consent before the enrollment. The studies were reviewed
and approved by the Internal Review Board of all participating institu-
tions, and performed in accordance with the Declaration of Helsinki. A
retrospective analysis of the three prospective clinical studies was per-
formed. The intention-to-treat population of each study was analyzed.
The chronic, accelerated or blast disease phase (CP, AP, BP) were
defined according to current European LeukemiaNet (ELN) criteria.10
The baseline risk assessment was made using Sokal,19 EURO,20 and
EUTOS21 risk scores. Cytogenetic analyses based on G- or Q-banding
were performed on bone marrow (BM) samples at baseline, after 6 and
12 months, and every 6 months thereafter, or in case of treatment fail-
ure. Cytogenetic responses were defined according to ELN criteria.10
After the achievement of a confirmed complete cytogenetic response
(CCyR), if less than 20 metaphases were available, the stability of CCyR
could be assessed by fluorescence-in situ-hybridization (FISH) analysis
on BM or peripheral blood (PB) cells (CCyR was defined as less than 1%
BCR-ABL1 positive nuclei over at least 200 cells).10 A qualitative reverse
transcription (RT) polymerase chain reaction (PCR) for BCR-ABL1 tran-
script was routinely performed at enrollment. Real-time quantitative
(RQ) PCR was performed at 3, 6, 12 months, and every 6 months there-
after, according to ELN and EUTOS recommendations.22–26 ABL1 was
used as housekeeping gene. A major molecular response (MMR or
MR3.0) was defined as a BCR-ABL1 transcript0.1%, while a deep
molecular response (MR4.0) was defined as a BCR-ABL1 tran-
script0.01% in samples with>10 000 ABL1 copies.22–26
Baseline characteristics of patients with different transcript types
were compared using the Student t test, Pearson’s chi square test or
Fisher’s exact test, as appropriate. The time to response were calcu-
lated from treatment start until the first achievement of response. The
cumulative incidences of response were estimated under consideration
of competing risks27,28 defined by progression and death. Comparisons
between cumulative incidences were performed by the Gray test.29
Overall survival (OS) was calculated from treatment start to death. All
deaths, by any cause and at any time (including deaths occurred after
IM discontinuation) were considered. Progression-free survival (PFS)
was calculated from treatment start to progression or death, whichever
came first. Progression was defined as the transformation to AP or BP
on IM or subsequent therapy. Failure-free survival (FFS) was calculated
from treatment start to IM failure, progression, or death, whichever
came first. Failures were retrospectively defined according to 2013
ELN criteria10; as the ELN criteria changed over time, not all the fail-
ures according to 2013 ELN criteria were followed by a change of
treatment. Probabilities of OS, PFS and FFS were estimated using the
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Kaplan-Meier method and compared by the log-rank test. A multivari-
ate Cox analysis30 was used to assess the relationship between various
predictors of interest and response or outcome. The proportional haz-
ard assumption was verified by Schoenfeld residuals analysis.
3 | RESULTS
3.1 | Patients
In all the 559 patients a qualitative RT-PCR assay was performed
before treatment start: 203 patients (36%) had a e13a2 transcript and
290 patients (52%) had a e14a2 transcript. All analyses and calculations
were made on these 493 patients. The remaining patients had both
e13a2 and e14a2 transcripts (N560, 11%), or other rare transcripts
(N56, 1%; e1a2 and e19a2 in 2 and 4 patients, respectively). Detailed
baseline characteristics according to the transcript type are presented
in Table I. The baseline characteristics of patients expressing both
e13a2 and e14a2 transcripts and patients with rare transcripts are pre-
sented in Supporting Information Table SI and SII. The patients with
e13a2 or e14a2 transcript were comparable for demographic and
hematologic characteristics, except for the proportion of male patients,
that was higher in the e13a2 group (P5 .050), and for the percentages
of eosinophils, that was significantly lower in the e13a2 group
(P5 .009). The patients distribution according to Sokal,19 EURO,20 and
EUTOS21 score was comparable. The proportion of patients with clonal
chromosomal abnormalities (CCA) in Philadelphia chromosome positive
TABLE I Comparison of patient characteristics at diagnosis
Characteristic e13a2 N5203 e14a2 N5 290 P
Age, years median (range) 52 (18-79) 52 (18-84) .374
Gender Male N (%) 133 (66) 164 (57) .050
ECOG 2, N (%) 43 (21) 62 (21) 1.000
Hb level, g/dL median (range) 12.0 (7.1-17.2) 12.3 (6.4-17.5) .413
PLT count, 103/lL median (range) 293 (115-4920) 401 (101-2770) .251
WBC count, 103/lL median (range) 61.6 (2.0-500.0) 52.2 (1.2-491.0) .174
Peripheral blasts, % median (range) 1.0 (0-9.5) 1.0 (0-9.5) .397
Eosinophils, % median (range) 1.8 (0-15.0) 2.0 (0-13.0) .009
Basophils, % median (range) 2.0 (0-19.0) 2.0 (0-16.0) .259
Spleen, cm median (range) 1 (0-24) 1 (0-22) .693
Sokal score, N (%):
· Low 86 (42) 108 (37) .525
· Intermediate 74 (36) 110 (38)
· High 43 (21) 72 (25)
EURO score, N (%):
· Low 90 (44) 124 (43) .322
· Intermediate 101 (50) 142 (49)
· High 12 (6) 24 (8)
EUTOS score, N (%):
· Low 188 (93) 267 (92) .662
· High 15 (7) 23 (8)
CCA Ph1 present, N (%) 7 (3) 9 (3) 1.000
Variant translocation present, N (%) 14 (7) 13 (4) .315
Derivative 9 deletions present, N (%) 27 (13) 27 (9) .188
Imatinib dose, N (%):
· 400 mg 163 (80) 208 (72) .034
· 800 mg 40 (20) 82 (28)
Abbreviations: CCA Ph1, clonal chromosome abnormalities in Ph1 cells; ECOG, performance status according to the Eastern Co-operative Oncology
Group (all enrolled patients were required to have ECOG performance status 0-2 at baseline); EUTOS, European Treatment and Outcome Study; Hb,
hemoglobin; PLT, platelet; WBC, white blood cells.
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(Ph1) cells at baseline, variant translocations or derivative 9 deletions
were similar in the 2 groups. In the e14a2 group, a slightly higher pro-
portion of patients was treated with IM 800 mg daily as initial dose
(28%, compared with 20% in the e13a2 group, P5 .034).
3.2 | Response and outcome by transcript type
The median follow-up was 76 months (range 49-94 months) and 75
months (range 7-99 months) in e13a2 and e14a2 patients, respectively
(P5 .763). The proportion of patients with an observation equal to or
longer than 60 months was similar: 96% and 94% (P 5.391) in e13a2
and e14a2 patients, respectively.
The cytogenetic and molecular response rates at milestones are
shown in Supporting Information Table SIII: the CCyR rates at 12
months were comparable (75% and 79% in patients with e13a2 or
e14a2 mRNA, P5 .274), but the rates of MMR at 18 months and MR4.0
at 36 months were significantly lower in patients with e13a2 transcript
(52% and 67%, P5 .001, and 20% and 30%, P5 .013, respectively). The
proportion of not evaluable patients was comparable in the 2 groups.
As far as the rapidity of response, the median time to CCyR was 6
months in both groups, with a comparable overall estimated probability
of CCyR: 89% and 88% in patients with e13a2 and e14a2 transcript,
P5 .916. The patients with e13a2 transcript achieved a MMR and a
MR4.0 significantly slower than patients with e14a2 transcript: the
median time to MMR was 12 and 6 months, with 83% and 88% overall
estimated probability of MMR in e13a2 patients and e14a2 patients
(P< .001), respectively; the median time to MR4.0 was 61 and 41
months and the overall estimated probability of MR4.0 was 52% and
67% in the 2 groups (P5 .001), respectively (Figure 1).
The 7-year estimated probabilities of OS (83% and 90%, P5 .017),
PFS (81% and 89%, P5 .005) and FFS (54% and 71%, P< .001) were
significantly lower in patients with e13a2 transcript (Figure 2). In multi-
variate Cox analysis,30 the transcript type retained its prognostic signif-
icance on time to MMR, time to MR4.0, OS, PFS and FFS (Supporting
Information Table SIV), when adjusted for other relevant variables.
The patients receiving a salvage therapy (one or more tyrosine
kinase inhibitors, conventional chemotherapy, allogeneic stem cell
transplantation) were 64 (31%) and 71 (24%) in the e13a2 and e14a2
groups, respectively. Molecular data after treatment change were not
prospectively collected, so the impact on molecular response cannot be
assessed. The patients who died after progression to advanced phase
were 13/64 (20%) and 13/71 (18%), respectively.
The responses and the survival probabilities of patients co-
expressing the e13a2 and the e14a2 transcripts were similar to or even
better than the ones of e14a2 patients (Supporting Information Figures
S1 and S2). The response and the outcome of patients with rare tran-
scripts are presented in Supporting Information Table SII.
3.3 | Prognostic impact of transcript type according to
the initial imatinib dose
Analyzing separately the patients treated with IM 400 mg (n5371;
e13a2 and e14a2 transcript in 163 and 208 patients, respectively) or
FIGURE 1 Time to response by transcript type. Estimates of (A)
time to complete cytogenetic response, (B) time to major molecular
response, and (C) time to deep molecular response (MR4.0),
according to the fusion transcript type (patients included: 203
patients with e13a2 transcript and 290 patients with e14a2
transcript)
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IM 800 mg daily (n5122; e13a2 and e14a2 transcript in 40 and 82
patients, respectively), the response differences according to the tran-
script type (e13a2 vs e14a2) were confirmed: the cumulative inciden-
ces of MMR were 84% and 89% in patients treated with standard-
dose IM (median time to MMR: 12 and 6 months, respectively,
P5 .001) and 73% and 82% in patients treated with high-dose IM
(median time to MMR: 15 and 6 months, respectively, P5 .026); the
cumulative incidences of MR4.0 were 57% and 68% in patients treated
with 400 mg (median time to MR4.0: 54 and 41 months, respectively,
P5 .024) and 30% and 60% in patients treated with 800 mg daily
(median time to MR4.0 not reached and 48 months, respectively,
P5 .007).
In patients treated with standard-dose IM, the transcript type was
able to predict significantly different 7-year probabilities of OS, PFS
and FFS (Figure 3). In the high-dose IM group, the patients with e13a2
transcript had inferior PFS (71% and 86%, P5 .039) and FFS (44% and
67%, P5 .011), but no difference could be detected in OS (82% and
87%, P5 .232) (Figure 3).
4 | DISCUSSION
The great majority of CML patients have a mRNA transcript with a
e13a2 or a e14a2 junction.1–3 The information on the prognostic
impact of BCR-ABL1 transcript type in ECP CML patients treated
frontline with IM is still limited to few studies. In 74 patients treated
with IM 400 mg it was found that the CCyR rate at one year was
higher in e14a2 patients than in e13a2 ones (54% vs 24%, P5 .01).11
In a much larger study of 1105 patients, it was found that the cumula-
tive probability of achieving MMR and MR4.0 was significantly higher in
e14a2 patients than in e13a2 ones.12 In 481 patients treated frontline
with IM or with second generation TKIs, the CCyR and the MMR rate
at several time points were higher in e14a2 patients.13 A MR4.0 was
reported more frequently in e14a2 patients than in e13a2 ones (57%
vs 27%, P5 .003).14 However, in only one study13 a difference in out-
come (transformation-free survival, 98% versus 91%, P5 .01) was
detectable; no differences in overall survival or other outcome meas-
ures were reported. A large analysis on 1494 European patients failed
to detect survival differences, considering either deaths for any reason
or CML-related deaths; responses and other outcome measures have
not been analyzed.15
In line with prior reports, we have also found that the e13a2 tran-
script was associated with a poorer response to IM: MMR and MR4.0
rates were significantly lower with a significantly longer time to the
first MMR and MR4.0. As predictable, since CCyR and MMR are the
best surrogate markers of the outcome,8–10 we also found that the
e13a2 transcript was associated with a poorer outcome (OS, PFS and
FFS). Moreover, the deep molecular response may predict the probabil-
ity of achieving a treatment-free remission (TFR).10 The differences
between transcripts were not influenced by confounding factors: the
analysis was performed considering the intention-to-treat population
of each protocol, the proportion of patients lacking of cytogenetic or
molecular evaluation (weighting as a negative result) was balanced
between the two groups, and the relative risk distribution according to
Sokal,19 EURO,20 and EUTOS21 scoring systems was comparable. By
multivariable analysis, the prognostic value of transcript type was even
stronger than that of any other variables.
There were some differences between the two groups. In the
e13a2 group there were more males, and males may have a worse
FIGURE 2 Outcome by transcript type. Estimates of (A) overall
survival, (B) progression-free survival, (C) failure-free survival,
according to the fusion transcript type (patients included: 203
patients with e13a2 transcript and 290 patients with e14a2 tran-
script). The definitions of progression and failure are detailed in the
methods section
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prognosis; moreover, in the same group the baseline percentage of
eosinophils in peripheral blood (PB) was lower, and eosinophils have
been shown to have a worse prognosis.20 More importantly, the pro-
portion of patients treated with IM 800 mg daily as initial dose was
lower in e13a2 group. High-dose IM (equal to or higher than 600 mg
daily) has not been approved yet as first-line therapy of CML patients
in CP. Four randomized studies comparing 400 mg versus 800 mg IM
daily have been published, three for patients of any risk category31–33
and one for high Sokal score patients only.17 A significant advantage of
high-dose treatment was shown in only one study,32 but in all four
studies there was a trend in favor of high doses. In our study, due to
the inclusion and exclusion criteria of studies CML/021 and CML/022,
all the patients treated with high dose IM had intermediate or high
Sokal score. To test if IM dose could have influenced the results of this
study, we made all calculations separately, according to the initial IM
dose, and we found that in e13a2 patients responses and outcomes
were poorer irrespective of IM dose, with the exception of OS in
patients treated with high-dose (no significant difference).
The difference between e13a2 and e14a2 patients is difficult to
understand and to explain. The e13a2 and e14a2 hybrid mRNA and
protein differ in size by 75 bases and 25 amino acids, respectively.
These sequences are a putative site for calcium-dependent lipid
FIGURE 3 Outcome by transcript type in patients treated with standard- or high-dose imatinib. Estimates of (A) overall survival, (B)
progression-free survival, (C) failure-free survival, according to the fusion transcript type in patients receiving standard-dose imatinib
(patients included: 163 patients with b2a2 transcript and 208 patients with b3a2 transcript). Estimates of (D) overall survival, (E)
progression-free survival, (F) failure-free survival, according to the fusion transcript type in patients receiving high-dose imatinib (patients
included: 40 patients with b2a2 transcript and 82 patients with b3a2 transcript; all patients treated with high-dose imatinib had intermedi-
ate or high Sokal score). The definitions of progression and failure are detailed in the methods section
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binding, but the exact function is currently unknown.1–3 With conven-
tional chemotherapy or alpha-interferon, the BCR-ABL1 transcript type
had no strong effects on the response and the outcome.4–7 Consider-
ing the selectivity of IM, the emergence of outcome differences
between e13a2 and e14a2 patients suggests a potential BCR-ABL1
dependent mechanism. A higher pCrKL/CrKl ratio at diagnosis has
been described in patients with a e13a2 transcript,11 but the higher
pre-treatment tyrosine kinase activity was not evaluated in a multivari-
ate analysis including other relevant variables (ie, disease score). We
may hypothesize a more efficient tyrosine kinase activity in e13a2
patients, but a systematic evaluation of the pre-treatment tyrosine
kinase activity has not been accomplished in our study. Conversely, the
junction sequences product of the BCR-ABL1 fusion can bind several
human leukocyte antigen (HLA) class I and II molecules, and to elicit
peptide-specific T-cell responses.34–38 We may speculate on a putative
different immunogenic ability of the e13a2 protein, which is shorter
than the e14a2 one and have different junctional sequences, but no
evidences supporting this hypothesis are available. Finally, the response
and outcome differences between e13a2 and e14a2 patients could be
due to the crystallographic structure of the BCR-ABL protein or to a
different interaction between the IM molecule and the p210 protein,
but clarifying data have not been published yet.
The current CML therapeutic scenario has been enriched by FDA
and EMA approval of nilotinib (NIL) and dasatinib (DAS) as frontline
treatment. In early CP CML, both drugs induced significantly superior
rates of cytogenetic and molecular responses as compared with
IM.39–42 So far, few data are available about the relationship between
the BCR-ABL1 transcript type and the response to second generation
TKIs: a preliminary study from the GIMEMA CML WP on 345 patients
treated with NIL based regimens, despite a trend for lower response
rates and inferior outcome in patients with e13a2 transcript, did not
detect significant differences between e13a2 and e14a2 patients.43
Another preliminary study from MD Anderson Cancer Center on 204
patients treated with NIL or DAS, reported a lower rate of molecular
responses and a trend for inferior EFS in e13a2 patients.44
We conclude that the e13a2 BCR-ABL1 fusion transcript affects
the rate, the depth, and the speed of the response to treatment with
imatinib firstline, and that including the transcript type in the calcula-
tion of the baseline risk scores may improve prognostic stratification
and may help the choice of the best treatment policy. More data and a
longer follow-up, are required to understand if the transcript type influ-
ences the immunologic control of residual disease, so affecting the
probability of achieving a TFR.
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